Mercury Laboratories [MERCURYLAB] vs Sun Pharmaceutical [SUNPHARMA] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Mercury Laboratories Ltd. wins in 6 metrics, Sun Pharmaceutical Industries Ltd. wins in 14 metrics, with 0 ties. Sun Pharmaceutical Industries Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Mercury Laboratories Ltd. | Sun Pharmaceutical Industries Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 18.15 | 36.73 | Mercury Laboratories Ltd. |
| Price-to-Book Ratio | 1.54 | 5.15 | Mercury Laboratories Ltd. |
| Debt-to-Equity Ratio | 10.77 | 6.68 | Sun Pharmaceutical Industries Ltd. |
| PEG Ratio | -1.11 | 3.59 | Sun Pharmaceutical Industries Ltd. |
| EV/EBITDA | 10.44 | 23.61 | Mercury Laboratories Ltd. |
| Profit Margin (TTM) | 6.20% | 19.21% | Sun Pharmaceutical Industries Ltd. |
| Operating Margin (TTM) | 8.99% | 26.17% | Sun Pharmaceutical Industries Ltd. |
| EBITDA Margin (TTM) | 8.99% | 26.17% | Sun Pharmaceutical Industries Ltd. |
| Return on Equity | 5.87% | 15.08% | Sun Pharmaceutical Industries Ltd. |
| Return on Assets (TTM) | 4.23% | 11.87% | Sun Pharmaceutical Industries Ltd. |
| Free Cash Flow (TTM) | $-50.39M | $119.44B | Sun Pharmaceutical Industries Ltd. |
| Dividend Yield | 0.82% | 0.97% | Sun Pharmaceutical Industries Ltd. |
| 1-Year Return | -11.83% | 7.10% | Sun Pharmaceutical Industries Ltd. |
| Price-to-Sales Ratio (TTM) | 1.12 | 7.05 | Mercury Laboratories Ltd. |
| Enterprise Value | $887.85M | $3,783.37B | Sun Pharmaceutical Industries Ltd. |
| EV/Revenue Ratio | 1.17 | 6.66 | Mercury Laboratories Ltd. |
| Gross Profit Margin (TTM) | 61.64% | 80.96% | Sun Pharmaceutical Industries Ltd. |
| Revenue per Share (TTM) | $635 | $237 | Mercury Laboratories Ltd. |
| Earnings per Share (Diluted) | $39.30 | $45.46 | Sun Pharmaceutical Industries Ltd. |
| Beta (Stock Volatility) | 0.44 | 0.11 | Sun Pharmaceutical Industries Ltd. |
Mercury Laboratories Ltd. vs Sun Pharmaceutical Industries Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Mercury Laboratories Ltd. | -2.06% | -2.39% | -0.16% | -5.13% | -9.16% | -9.32% |
| Sun Pharmaceutical Industries Ltd. | -0.09% | 0.96% | -3.84% | 1.28% | 0.50% | 4.93% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Mercury Laboratories Ltd. | -11.83% | -5.41% | 16.63% | 72.97% | 2,064.80% | 2,064.80% |
| Sun Pharmaceutical Industries Ltd. | 7.10% | 82.23% | 170.41% | 143.23% | 656.74% | 2,541.29% |
Performance & Financial Health Analysis: Mercury Laboratories Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | MERCURYLAB | SUNPHARMA |
|---|---|---|
| Market Information | ||
| Market Cap | ₹855.84M | ₹3.88T |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 19 | 3,903,142 |
| 90 Day Avg. Volume | 59 | 3,253,866 |
| Last Close | ₹759.00 | ₹1,806.00 |
| 52 Week Range | ₹620.55 - ₹976.00 | ₹1,548.00 - ₹1,916.60 |
| % from 52W High | -22.23% | -5.77% |
| All-Time High | ₹1,303.00 (Jan 08, 2024) | ₹1,960.35 (Sep 30, 2024) |
| % from All-Time High | -41.75% | -7.87% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.06% | 0.14% |
| Quarterly Earnings Growth | -0.16% | 0.16% |
| Financial Health | ||
| Profit Margin (TTM) | 0.06% | 0.19% |
| Operating Margin (TTM) | 0.09% | 0.26% |
| Return on Equity (TTM) | 0.06% | 0.15% |
| Debt to Equity (MRQ) | 10.77 | 6.68 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹464.51 | ₹324.46 |
| Cash per Share (MRQ) | ₹23.55 | ₹115.87 |
| Operating Cash Flow (TTM) | ₹-12,625,000 | ₹110.84B |
| Levered Free Cash Flow (TTM) | ₹31.45M | ₹109.29B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.82% | 0.97% |
| Last 12-Month Dividend | ₹7.00 | ₹16.50 |
Valuation & Enterprise Metrics Analysis: Mercury Laboratories Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | MERCURYLAB (Apr 26, 2026) | SUNPHARMA (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 18.15 | 36.73 |
| Forward P/E | N/A | 29.48 |
| PEG Ratio | -1.11 | 3.59 |
| Price to Sales (TTM) | 1.12 | 7.05 |
| Price to Book (MRQ) | 1.54 | 5.15 |
| Market Capitalization | ||
| Market Capitalization | ₹855.84M | ₹3.88T |
| Enterprise Value | ₹887.85M | ₹3.78T |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.17 | 6.66 |
| Enterprise to EBITDA | 10.44 | 23.61 |
| Risk & Other Metrics | ||
| Beta | 0.44 | 0.11 |
| Book Value per Share (MRQ) | ₹464.51 | ₹324.46 |
Financial Statements Comparison: Mercury Laboratories Ltd. vs Sun Pharmaceutical Industries Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | MERCURYLAB (2025) | SUNPHARMA (2025) |
|---|---|---|
| Revenue/Sales | 751.01M | 520.41B |
| Cost of Goods Sold | 289.16M | 121.98B |
| COGS % of Revenue | 38.5% | 23.4% |
| Gross Profit | 461.85M | 398.44B |
| Gross Margin | 61.5% | 76.6% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | 74.14M | 125.81B |
| Operating Margin | 9.9% | 24.2% |
| EBITDA | 109.74M | 167.25B |
| EBITDA Margin | 14.6% | 32.1% |
| Pre-Tax Income | 46.62M | 137.52B |
| Pre-Tax Income % of Revenue | 6.2% | 26.4% |
| Income Tax | 15.17M | 27.72B |
| Income Tax % of Revenue | 2.0% | 5.3% |
| Net Income (Profit) | 31.45M | 109.65B |
| Profit Margin | 4.2% | 21.1% |
Balance Sheet & Liquidity Metrics
| Metric | MERCURYLAB (2025) | SUNPHARMA (2025) |
|---|---|---|
| Cash & Equivalents | 3.32M | 102.69B |
| Total Current Assets | 401.60M | 526.24B |
| Total Current Assets % of Revenue | 53.5% | 101.1% |
| Total Current Liabilities | 150.76M | 181.94B |
| Total Current Liabilities % of Revenue | 20.1% | 35.0% |
| Long-Term Debt | 37.83M | 3.58B |
| Long-Term Debt % of Revenue | 5.0% | 0.7% |
| Total Shareholders Equity | 535.69M | 724.86B |
| Retained Earnings | 86.56M | 578.62B |
| Retained Earnings % of Revenue | 11.5% | 111.2% |
| Property, Plant & Equipment | 85.40M | 100.36B |
Cash Flow Statement Comparison
| Metric | MERCURYLAB (2025) | SUNPHARMA (2025) |
|---|---|---|
| Operating Cash Flow | -12.63M | 110.84B |
| Operating Cash Flow % of Revenue | -1.7% | 21.3% |
| Capital Expenditures | -90.40M | -20.68B |
| Free Cash Flow | -50.39M | 119.44B |
| FCF Margin | -6.7% | 23.0% |
| Debt Repayment | N/A | -43.44B |
| Common Stock Repurchase | N/A | -29.00B |
Short Interest & Institutional Ownership Analysis
| Metric | MERCURYLAB | SUNPHARMA |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 1.20M | 2.40B |
| Float Shares | 165,470 | 1.07B |
| % Held by Insiders | 86.33% | 55.62% |
| % Held by Institutions | 0.00% | 28.69% |
| % Held by Public | 13.67% | 15.69% |
Dividend Analysis & Yield Comparison: Mercury Laboratories Ltd. vs Sun Pharmaceutical Industries Ltd.
| Metric | MERCURYLAB | SUNPHARMA |
|---|---|---|
| Last 12-Month Dividend | ₹7.00 | ₹16.50 |
| Last 12-Month Dividend Yield | 0.82% | 0.97% |
| 3-Year Avg Annual Dividend | ₹4.67 | ₹17.33 |
| 3-Year Avg Dividend Yield | 0.43% | 0.51% |
| 3-Year Total Dividends | ₹14.00 | ₹52.00 |
| Ex-Dividend Date | Aug 06, 2025 | Feb 05, 2026 |